Advertisement
Screener

MARKER THERAPEUTICS, INC. (MRKR) Net Income (Loss) Attributable to Parent, Diluted

2.8 / 5 stars · 68/120 Roast Me

MARKER THERAPEUTICS, INC. Net Income (Loss) Attributable to Parent, Diluted

MARKER THERAPEUTICS, INC. (MRKR) reported Net Income (Loss) Attributable to Parent, Diluted of -$10.98 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-23.

Discontinued › Income Statement

us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2018-03-23

  • MARKER THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2017-12-31 was -$2.68M.
  • MARKER THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2017-09-30 was -$3.99M.
  • MARKER THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2017-06-30 was -$1.89M, a 183.15% decline year-over-year.
  • MARKER THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2017-03-31 was -$2.42M.
  • MARKER THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for fiscal 2017 was -$10.98M.
  • MARKER THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for fiscal 2016 was -$5.31M.
  • MARKER THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for fiscal 2015 was -$34.07M.
Period endNet Income (Loss) Attributable to Parent, Diluted 3 monthNet Income (Loss) Attributable to Parent, Diluted 3 month as first filedNet Income (Loss) Attributable to Parent, Diluted 6 monthNet Income (Loss) Attributable to Parent, Diluted 6 month as first filedNet Income (Loss) Attributable to Parent, Diluted 9 monthNet Income (Loss) Attributable to Parent, Diluted 12 month
2017-12-31-$2.68M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-23
-$6.67M
derived: sum of 2 quarters · filed 2018-03-23
-$8.56M
derived: sum of 3 quarters · filed 2018-03-23
-$10.98M
10-K · filed 2018-03-23
2017-09-30-$3.99M
10-Q · filed 2017-11-14
-$5.88M
derived: sum of 2 quarters · filed 2017-11-14
-$8.30M
10-Q · filed 2017-11-14
-$9.88M
derived: sum of 4 quarters · filed 2018-03-23
2017-06-30-$1.89M
10-Q · filed 2017-08-07
-$4.31M
10-Q · filed 2017-08-07
-$5.89M
derived: sum of 3 quarters · filed 2018-03-23
-$7.99M
derived: sum of 4 quarters · filed 2018-03-23
2017-03-31-$2.42M
derived: 10-K 12 month − 3 quarters · filed 2018-03-23
-$4.00M
derived: sum of 2 quarters · filed 2018-03-23
-$6.10M
derived: sum of 3 quarters · filed 2018-03-23
-$3.82M
derived: sum of 4 quarters · filed 2018-03-23
2016-12-31-$1.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-23
-$3.68M
derived: sum of 2 quarters · filed 2018-03-23
-$1.40M
derived: sum of 3 quarters · filed 2018-03-23
-$5.31M
10-K · filed 2018-03-23
2016-09-30-$2.10M
10-Q · filed 2017-11-14
$174.18K
derived: sum of 2 quarters · filed 2017-11-14
-$3.73M
10-Q · filed 2017-11-14
2016-06-30$2.28M
10-Q · filed 2017-08-07
$2.28M
10-Q · filed 2016-08-15
-$1.27M
10-Q · filed 2017-08-07
-$1.27M
10-Q · filed 2016-08-15
2015-12-31-$1.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14
$26.85M
derived: sum of 2 quarters · filed 2017-03-14
-$33.37M
derived: sum of 3 quarters · filed 2017-03-14
-$34.07M
10-K · filed 2017-03-14
2015-09-30$28.50M
10-Q · filed 2016-11-04
-$31.71M
derived: sum of 2 quarters · filed 2016-11-04
-$32.41M
10-Q · filed 2016-11-04
2015-06-30-$60.22M
10-Q · filed 2016-08-15
-$60.92M
10-Q · filed 2016-08-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Rocket One Inc. (RKTO)United States$0.019B
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Cocrystal Pharma, Inc. (COCP)United States$0.022B
Lipocine Inc. (LPCN)United States$0.017B-1.79
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66